These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 30858217)
21. Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept. Cojutti PG; Rinaldi M; Gatti M; Tedeschi S; Viale P; Pea F Int J Antimicrob Agents; 2021 Nov; 58(5):106445. PubMed ID: 34614441 [TBL] [Abstract][Full Text] [Related]
22. Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review. Matt M; Duran C; Courjon J; Lotte R; Moing VL; Monnin B; Pavese P; Chavanet P; Khatchatourian L; Tattevin P; Cattoir V; Lechiche C; Illes G; Lacassin-Beller F; Senneville E; Dinh A; J Glob Antimicrob Resist; 2021 Jun; 25():341-345. PubMed ID: 33962065 [TBL] [Abstract][Full Text] [Related]
23. Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility. Almangour TA; Perry GK; Terriff CM; Alhifany AA; Kaye KS Diagn Microbiol Infect Dis; 2019 Mar; 93(3):213-218. PubMed ID: 30396697 [TBL] [Abstract][Full Text] [Related]
24. Dalbavancin: a new option for the treatment of gram-positive infections. Lin SW; Carver PL; DePestel DD Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624 [TBL] [Abstract][Full Text] [Related]
25. [Evaluation of clinical evidence for dalbavancin]. Rodríguez-Pardo D Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():33-37. PubMed ID: 28129819 [TBL] [Abstract][Full Text] [Related]
26. French national cohort of first use of dalbavancin: A high proportion of off-label use. Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E; Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471 [TBL] [Abstract][Full Text] [Related]
27. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens. Das B; Sarkar C; Biswas R; Pandey S Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524 [TBL] [Abstract][Full Text] [Related]
28. Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study. Buzón Martín L; Mora Fernández M; Perales Ruiz JM; Ortega Lafont M; Álvarez Paredes L; Morán Rodríguez MA; Fernández Regueras M; Machín Morón MA; Mejías Lobón G Rev Esp Quimioter; 2019 Dec; 32(6):532-538. PubMed ID: 31642637 [TBL] [Abstract][Full Text] [Related]
29. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Andes D; Craig WA Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987 [TBL] [Abstract][Full Text] [Related]
31. Dalbavancin for the management of osteomyelitis: a major step forward? Almangour TA; Alhifany AA J Antimicrob Chemother; 2020 Oct; 75(10):2717-2722. PubMed ID: 32457989 [TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of teicoplanin for bone and joint infections: results of a community-based trial. Weinberg WG South Med J; 1993 Aug; 86(8):891-7. PubMed ID: 8351549 [TBL] [Abstract][Full Text] [Related]
33. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review. Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683 [TBL] [Abstract][Full Text] [Related]
34. Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study. Morata Ruiz L; Ruggieri A; Falcone M; Pasquau Liaño J; Gentile I; Salavert Lletí M; Moreno Núñez L; Cascio A; Tascini C; Loeches Yagüe M; De Rosa FG; Ori A; Comandini A; Cattaneo A; Grossi PA; J Glob Antimicrob Resist; 2024 Mar; 36():200-209. PubMed ID: 38211660 [TBL] [Abstract][Full Text] [Related]
35. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Kim A; Kuti JL; Nicolau DP Expert Opin Investig Drugs; 2007 May; 16(5):717-33. PubMed ID: 17461743 [TBL] [Abstract][Full Text] [Related]
36. Experience in the use of dalbavancin in diabetic foot infection. Navarro-Jiménez G; Fuentes-Santos C; Moreno-Núñez L; Alfayate-García J; Campelo-Gutierrez C; Sanz-Márquez S; Pérez-Fernández E; Velasco-Arribas M; Hervás-Gómez R; Martín-Segarra O; Losa-García JE Enferm Infecc Microbiol Clin (Engl Ed); 2022; 40(6):296-301. PubMed ID: 35490091 [TBL] [Abstract][Full Text] [Related]
37. Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic-A Single-Center Retrospective Study. Ioannou P; Wolff N; Mathioudaki A; Spanias C; Spernovasilis N; Kofteridis DP Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508301 [TBL] [Abstract][Full Text] [Related]
38. Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model. Baldoni D; Furustrand Tafin U; Aeppli S; Angevaare E; Oliva A; Haschke M; Zimmerli W; Trampuz A Int J Antimicrob Agents; 2013 Sep; 42(3):220-5. PubMed ID: 23880168 [TBL] [Abstract][Full Text] [Related]
39. Teicoplanin in the treatment of bone and joint infections. Teicoplanin Bone and Joint Cooperative Study Group, USA. LeFrock JL; Ristuccia AM; Ristuccia PA; Quenzer RW; Haggerty PG; Allen JE; Lettau LA; Schwartz R; Appleby D Eur J Surg Suppl; 1992; (567):9-13. PubMed ID: 1381644 [TBL] [Abstract][Full Text] [Related]
40. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs. Gatti M; Andreoni M; Pea F; Viale P Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]